CoChat

Once-Daily Atomoxetine for Adult Attention-Deficit/Hyperactivity Disorder: A 6-Month, Double-Blind Trial

Adler, Lenard A., Spencer, Thomas, Brown, Thomas E., Holdnack, James, Saylor, Keith, Schuh, Kory, Trzepacz, Paula T., Williams, David W., Kelsey, Douglas · 2009 · Journal of Clinical Psychopharmacology
Cited by 142

The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.

Abstract

This randomized, double-blind, placebo-controlled, 6-month trial examined the efficacy and safety of once-daily morning-dosed atomoxetine in adult patients with attention-deficit/hyperactivity disorder (ADHD) and the efficacy of atomoxetine in ameliorating symptoms through the evening hours. Patients received once-daily atomoxetine (n = 250) or placebo (n = 251) in the morning for approximately 6 months. The efficacy measures included the Adult ADHD Investigator Symptom Rating Scale (AISRS), Conners' Adult ADHD Rating Scale-Investigator Rated: Screening Version, Clinical Global Impressions-ADHD-Severity of Illness, and Adult ADHD Quality of Life Scale. Overall, 94 patients randomized to atomoxetine and 112 patients randomized to placebo completed the study. On the AISRS total score, Conners' Adult ADHD Rating Scale-Investigator Rated: Screening Version evening index total score, Clinical Global Impressions-ADHD-Severity of Illness score, and Adult ADHD Quality of Life Scale total score, atomoxetine was statistically superior to placebo at the 10-week and 6-month time points. From the visitwise analysis, the mean (SD) AISRS total scores for atomoxetine decreased from 38.2 (7.5) at baseline to 21.4 (12.3) at the 6-month end point compared with 38.6 (7.0) to 25.8 (13.2) for placebo (P = 0.035). Nausea, dry mouth, fatigue, decreased appetite, urinary hesitation, and erectile dysfunction were the treatment-emergent adverse events reported significantly more often with atomoxetine. Discontinuations due to adverse events were 17.2% and 5.6% for atomoxetine and placebo, respectively (P < 0.001). Once-daily morning-dosed atomoxetine is efficacious for treating ADHD in adults when measured 10 weeks and 6 months after initiating treatment. Atomoxetine demonstrated significant efficacy that continued into the evening. Adverse events were similar to previous trials.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/jcp.0b013e318192e4a0

Cites

15 of 15 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 6

  1. Faraone, 2007, ADHD in adults-a familiar disease with unfamiliar challenges., CNS Spectr, 12, 14, 10.1017/S1092852900003801 · DOI
  2. Adler, 2006, Safety and tolerability of once versus twice daily atomoxetine in adults with ADHD., Ann Clin Psychiatry, 18, 107, 10.1080/10401230600614603 · DOI · Paper page
  3. Adler, 2005, Training raters to assess adult ADHD: reliability of ratings., J Atten Disord, 8, 121, 10.1177/1087054705277168 · DOI · Paper page
  4. Brod, 2005, Conceptualization and assessment of quality of life for adults with attention-deficit/hyperactivity disorder., Prim Psychiatry, 12, 58
  5. Adler, 2002, Management of ADHD in adults., J Clin Psychiatry, 63, 29
  6. Adler, 2008, Long-term, open-label safety and efficacy of atomoxetine in adults with ADHD: final report of a 4-year study., J Atten Disord, 12, 248, 10.1177/1087054708316250 · DOI · Paper page

Cited by

See all 142

Metadata

Authors
Adler, L. A., Spencer, T., Brown, T. E., Holdnack, J., Saylor, K., Schuh, K., Trzepacz, P. T., Williams, D. W., & Kelsey, D.
Venue
Journal of Clinical Psychopharmacology
Published
2009-02
Volume
29
Issue
1
Pages
44-50
ISSN
0271-0749 (ISSN-L)
OpenAlex
W2077367843
Cited by
142
References
15
FWCI
11.07
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.